New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
May 4, 2020 - Tolmar Pharmaceuticals announced the FDA approval of Fensolvi (leuprolide acetate), for the treatment of pediatric patients 2 years of age and older with central precocious puberty (CPP).
Download PDF
Return to publications
